Physician profile
John William Thomas
NPI 1306342076
$494.54
in general payments reported to CMS, 2019-2025
17 companies · $324 in 2025
The $324 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $94.89 · 2024: $75.81 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $110.32 | 2023-2025 | |
| Abbvie INC. | $66.55 | 2025 | |
| Tersera Therapeutics LLC | $31.65 | 2025 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $26.17 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $26.16 | 2025 | |
| Csl Behring | $25.22 | 2024 | Hizentra |
| Kyowa Kirin, INC. | $24.35 | 2025 | |
| Puma Biotechnology, INC. | $24.01 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.48 | 2025 | Danziten, Vivimusta |
| Rigel Pharmaceuticals, INC. | $21.03 | 2024 | Rezlidhia, Tavalisse |
| Daiichi Sankyo INC. | $20.87 | 2025 | Datroway |
| Pharmaessentia USA Corporation | $19.66 | 2025 | Besremi |
| Alnylam Pharmaceuticals INC. | $18.42 | 2025 | Givlaari |
| Astrazeneca Pharmaceuticals LP | $15.74 | 2024 | |
| Eisai INC. | $15.21 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fennec Pharmaceuticals, INC. | $13.88 | 2025 | Fyarro |
| Dendreon Pharmaceuticals LLC | $13.82 | 2024 | Provenge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.